vimarsana.com

Page 3 - மாஸ்ட் செல் செயல்படுத்தல் நோய்க்குறி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nearly $100M in Long COVID Funding Introduced in Congress

Nearly $100M in Long COVID Funding Introduced in Congress Historic bipartisan act focuses on research, treatment, disparities of debilitating diseases affecting millions of Americans News provided by Share this article Share this article LOS ANGELES, May 27, 2021 /PRNewswire/ Rep. Don Beyer (D-VA) and Rep. Jack Bergman (R-MI) have introduced the historic COVID-19 Long Haulers Act (H.R. 2754) bipartisan legislation authorizing and funding research and education initiatives benefiting so-called long haulers, an estimated 25–35% of COVID-19 patients who experience long-term effects of the virus. Solve M.E. and members of the Long COVID Alliance worked closely with Representative Beyer s office to help craft data-driven policy solutions that meet the diverse needs of ALL long haulers and post-infectious illness patients.

GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation Forum

GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation Forum LAS VEGAS, NV / ACCESSWIRE / April 27, 2021 / GB Sciences (GBS), Inc. (OTCQB:GBLX), a leading phytomedicine research and biopharmaceutical development company, will be featured during the SPOTLIGHT SHOWCASE at the SACHS Associates 4th Annual Neuroscience Innovation Forum (NIF) for Business Development, Licensing & Investment from April 28 to April 30. The SACHS NIF, which is entirely virtual, will include a SPOTLIGHT SHOWCASE session describing GB Sciences recent pivot and novel drug development pipeline. In addition, Dr. Andrea Small-Howard, the Chief Science Officer and Director of GB Sciences, is an invited speaker on the Pain, Migraines, and Addiction Panel during a live session on Therapeutics Day 2, April 29 at 11:50 a.m. EDT.

GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation Forum

GB Sciences Featured & Speaking at the SACHS Associates 4th Annual Neuroscience Innovation Forum
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.

GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals

Press release content from Newswire. The AP news staff was not involved in its creation. GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals April 20, 2021 GMT GB Sciences and Purisys Announce Preferred Supplier Relationship to Advance Cannabinoid-Containing Pharmaceuticals LAS VEGAS - April 20, 2021 - ( Newswire.com ) GB Sciences, Inc. (OTCQB: GBLX) and Purisys, LLC, the global industry leader in ultra-high purity, pharmaceutical grade cannabinoid supply, today announced that GB Sciences has selected Purisys as their preferred vendor for the active pharmaceutical ingredients (“APIs”) used in formulating GB Sciences’ proprietary, cannabinoid-containing, optimized therapeutic mixtures (OTM). “To achieve standardization in our cannabinoid-containing, optimized therapeutic mixtures, GB Sciences is moving away from using materials extracted from the cannabis plant in favor of OTM formulations incorporating ident

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.